Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AXB-10507 is a rat surrogate bispecific VHH (heavy-chain variable domain) antibody targeting rat properdin (factor P, fP) and serum albumin. Developed by Alexion (AstraZeneca Rare Disease), AXB-10507 is used as a preclinical tool to evaluate the therapeutic potential of properdin inhibition, serving as a surrogate for the clinical-stage humanized bispecific VHH antibody ALXN1820 (tarperprumig). AXB-10507 selectively inhibits alternative pathway (AP) complement activation by preventing C3/C5 convertase formation. In preclinical models of experimental autoimmune vasculitis (EAV), subcutaneous administration of AXB-10507 significantly reduced hematuria and proteinuria, and protected against glomerular and tubular damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AXB-10507.